Receiveable Turnover: An accounting measure used to quantify a firm's effectiveness in extending credit as well as collecting debts. Calculated as: Total Revenues / Accounts Receivable
Esperion Therapeutics, Inc. (ESPR) had Receiveable Turnover of 2.88 for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$403.13M |
|
$-22.68M |
|
$129.22M |
|
$273.91M |
|
$342.86M |
|
$60.27M |
|
$-81.11M |
|
$-20.84M |
|
$-20.84M |
|
$-22.68M |
|
$-22.68M |
|
$-22.68M |
|
$-22.68M |
|
$60.27M |
|
$63.38M |
|
207.87M |
|
207.87M |
|
$-0.11 |
|
$-0.11 |
|
| Balance Sheet Financials | |
$462.57M |
|
$0.34M |
|
$3.32M |
|
$465.89M |
|
$300.81M |
|
$249.48M |
|
$467.04M |
|
$767.85M |
|
$-301.96M |
|
$-302.02M |
|
$-301.96M |
|
245.22M |
|
| Cash Flow Statement Financials | |
$-13.09M |
|
-- |
|
$36.18M |
|
$144.76M |
|
$167.85M |
|
$23.09M |
|
$9.87M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.54 |
|
-- |
|
-- |
|
-4.75 |
|
-0.83 |
|
67.95% |
|
14.95% |
|
14.95% |
|
15.72% |
|
-5.17% |
|
-5.63% |
|
$-13.09M |
|
-- |
|
-- |
|
-- |
|
0.87 |
|
1.23 |
|
|
Receiveable Turnover |
2.88 |
126.93 |
|
7.51% |
|
7.51% |
|
-4.87% |
|
43.22% |
|
$-1.23 |
|
$-0.06 |
|
$-0.06 |
|